• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar

information for practice

news, new scholarship & more from around the world


advanced search
  • gary.holden@nyu.edu
  • @ Info4Practice
  • Archive
  • About
  • Help
  • Browse Key Journals
  • RSS Feeds

Norway becomes the first country to publicly fund generic ketamine for depression

Drug Science
Drug Science

Ketamine was synthesized in 1962 and approved for anesthesia in the United States in 1970. At lower, subanesthetic doses, ketamine produces profound alterations in consciousness. Patients experience changes in perception, emotions, body awareness, and sense of self. This feeling of distance from the body and self led to its initial classification as a “dissociative anesthetic.”
The psychotherapeutic potential of ketamine was recognized long before modern antidepressant studies. During the 1970s and 1980s, psychiatrists in Iran and the former Soviet Union experimented with ketamine-assisted psychotherapy, using the altered state itself as a catalyst for psychological change.

Posted in: News on 06/02/2026 | Link to this post on IFP |
Share

Primary Sidebar

Categories

Category RSS Feeds

  • Calls & Consultations
  • Clinical Trials
  • Funding
  • Grey Literature
  • Guidelines Plus
  • History
  • Infographics
  • Journal Article Abstracts
  • Meta-analyses - Systematic Reviews
  • Monographs & Edited Collections
  • News
  • Open Access Journal Articles
  • Podcasts
  • Video

© 1993-2026 Dr. Gary Holden. All rights reserved.

gary.holden@nyu.edu
@Info4Practice